Keryx Biopharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference Presentation Scheduled for Wednesday, December 11th at 2:10 p.m. ET NEW YORK, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 24^th Annual Oppenheimer Healthcare Conference, being held on Wednesday, December 11^th, in New York City. Mr. Bentsur's presentation is scheduled to begin at 2:10 pm ET. A live audio webcast of Mr. Bentsur's presentation will be accessible within the Media section of the Company's Website at http://www.keryx.com/webcasts-presentations. An archived version of this webcast will be available following the conclusion of the live presentation. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate coordination complex), an oral, ferric iron-based compound. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA).The Company's New Drug Application (NDA) is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014.The Marketing Authorization Application filing with the European Medicines Agency (EMA) is pending submission.The Company is also developing Zerenex in the U.S. for the management of elevated phosphorus and iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx is headquartered in New York City. CONTACT: KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: email@example.com Keryx Logo
Keryx Biopharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.